Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0036

Scientific exchange · Dr. Valentina Hayashi

30 Apr 2026 · Phone · Dr. Valentina Hayashi, Hospital Clínic Barcelona · MSL Rachel Adeyemi · Vantrexa

ReviewedManualENG-0036—

Capture insight from this engagement

Location: Hospital Clínic Barcelona
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Duration of response

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Scientific exchange with oncology pharmacist at Hospital Clínic Barcelona. Discussed elderly / ecog 2 patients, duration of response.

Insights captured (1)

Capture insight

INS-0009High
Elderly / ECOG 2 patients
Elderly / ECOG 2 patients: interest in collaboration reported by oncology pharmacist (ES).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 4
Actionability: 5

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0036

Audit history (0)

All create, update and approval events for this record

No audit events in sample data